glp-1 agonists and inflammation Health Feed GLP-1 Receptor Agonists Reduce Inflammation

For Ozempic, which is FDA-approved for type 2 diabetes, the dosing schedule starts at 0.25 mg and escalates, with options to increase to 0.5 mg at week five, then 1.0 mg, and potentially up to 2.0 mg

Utreglutide (GL0034) Utreglutide is a once-weekly GLP-1 RA administered subcutaneously (41)

10397, pp

Aging (Albany NY) (2021) 13(14):1901327

Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, overcame this peptide problem by adding a security guard to their oral medication

This may be especially likely if you are transitioning off tirzepatide, the most powerful obesity treatment on the market, or have stepped down to a lower dose in order to reduce the risk of side effects